Potential Weak Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Trimethoprim is primarily eliminated by the kidney and in vitro data suggest that it inhibits the renal transporters OCT2 and MATE1, and could therefore potentially decrease emtricitabine renal elimination (via inhibition of MATE1). A pharmacokinetic interaction with tenofovir is unlikely as tenofovir is excreted by different renal transporters. No a priori dosage adjustment is recommended in patients with normal renal function.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking